Protocol Ledger

NCT05318521 · Phase III · ACTIVE NOT RECRUITING

RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee

Interventional Phase III clinical trial protocol NCT05318521 sponsored by Overseas Pharmaceuticals in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-10 Enrollment: 500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05318521
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05318521
Protocol FieldVerified Registry Value
NCT IdentifierNCT05318521
Consolidated Lead SponsorOverseas Pharmaceuticals
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment500 participants (ESTIMATED)
Registered Start Date2021-12-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05318521
Hospital Research SiteLocationSite Profile
Coastal Carolina Research CenterNorth Charleston, SCOpen Hospital Dossier ->
Taipei Medical University Shuang Ho HospitalNew Taipei City, TaiwanOpen Hospital Dossier ->
China Medical University HospitalTaichung, TaiwanOpen Hospital Dossier ->
Taipei Medical University HospitalTaipei, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI